Vitamin D Signaling in Human Health and Diseases - 5 articles Nov 2026
Summary by Claude AI - Nov 2026
Editorial
Int. J. Mol. Sci. 2026, 27, 9463 is an editorial, not a study. It's Daniela Rovito's (IGBMC, Strasbourg) introduction to the Special Issue "Vitamin D Signaling in Human Health and Diseases," published 23 Oct 2026 (Editorial). It argues that vitamin D is better understood as a network of metabolites, receptors, and transcriptional partners than as a single ligand-receptor axis. It introduces five papers:
1. Association of Vitamin D Receptor Gene Polymorphisms with Serum 25-Hydroxyvitamin D Levels in Lithuanian Adults with Atopic Dermatitis: A Case–Control Study
Briedė et al. · case–control study · May 2026 · DOI · PubMed
The authors genotyped six VDR SNPs (rs3847987, TaqI rs731236, ApaI rs7975232, BsmI rs1544410, FokI rs2228570, rs11168293) in 91 adults with atopic dermatitis and 102 controls. Genotype and allele frequencies were the same in patients and controls. Within the cohort:
- The TaqI G and BsmI T alleles were more common in people with 25(OH)D above 30 ng/mL.
- The ApaI C allele went with lower odds of being above 30 ng/mL.
- The rs11168293 T allele was more common in people with eosinophil counts of about 300 cells/µL or more.
The editorial points out that these links did not survive correction for multiple testing, so the authors suggest VDR variation may affect disease-related biomarkers rather than susceptibility.
2. Search for Potential VDR/Partner Composite Elements in Regulatory DNA of Genes Associated with Respiratory Infections and Atopic Diseases
Popov et al. · original research (in silico plus cell culture) · Dec 2025 · DOI · PubMed
Classic VDR/RXRA binding motifs show up in only about 11.5% of VDR ChIP-seq peaks, so the authors looked for other VDR partners. They used Web-MCOT motif searches, AlphaFold 3 modeling of the protein complexes, and RT-PCR in U937 macrophage-like cells treated with calcitriol. They predicted new VDR/NR2C2 and VDR/PPARG composite elements in immune genes. The pairing may act together with VDR/RXRA at IRF5 (NR2C2) and at MAPK13 (PPARG). IRF5 responded most strongly. Binding was not directly demonstrated.
3. Epigenetic Mechanisms of Vitamin D in the Aging Process: A Narrative Review
Guo, Yan, Zhao, Mao · narrative review · July 2026 · DOI · PubMed
This review covers age-related epigenetic changes: DNA methylation drift, histone changes, chromatin remodeling and non-coding RNA. It then describes how VDR signaling interacts with each, with sections on the immune, musculoskeletal and nervous systems.
- Trial evidence: large RCTs show little benefit from vitamin D alone. Benefits appear mainly when it's combined with exercise and nutrition. It cites the DO-HEALTH analysis, in which omega-3 slowed several epigenetic clocks, while vitamin D alone had no significant effect.
- Limits: people vary widely in response, the dose–response curve is J-shaped, and some tissues are hard to reach.
- Dosing advice: if 25(OH)D is below 50 nmol/L, take 800–2000 IU/day to reach 75–125 nmol/L. If 25(OH)D is 50 nmol/L or higher, don't supplement without a biochemical reason.
4. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease: Molecular Mechanisms and Clinical Implications—A Narrative Review
Fuentes-Barría et al. · narrative review · Mar 2026 · DOI · PubMed
Mechanisms: in liver cells, calcitriol lowers proinflammatory cytokines, improves insulin sensitivity, activates AMPK, inhibits mTOR and regulates lipid handling. Together these reduce fat buildup in the liver. The review also covers the liver–fat tissue axis.
Clinical evidence: supplementation may improve liver enzymes, insulin resistance and lipids. Results vary with dose, starting vitamin D level and the patient, and study designs are inconsistent. The authors view vitamin D as adjunctive rather than primary therapy outside confirmed deficiency. Optimal dose, duration and long-term outcomes are still unknown.
5. Pathophysiological Role of Vitamin D Deficiency in Down Syndrome: Insights into Metabolic Dysfunction and Sarcopenia
Valle et al. · review · Nov 2025 (Vol. 26) · DOI · PubMed
People with Down syndrome are often vitamin D deficient. They also tend to have low muscle tone, excess weight, thyroid problems and immune dysregulation. Together these raise the risk of falls, sarcopenia, sarcopenic obesity and long-term disability.
The review covers how low vitamin D affects insulin signaling, fat tissue metabolism, inflammation and muscle strength. The proposed mechanisms are chronic inflammation, oxidative stress, mitochondrial damage and disrupted adipokine signaling. The authors propose composite biomarker panels combining 25(OH)D with cytokines, adipokines, myokines, and functional muscle measures to guide personalized care. Optimal dosing is still unresolved.
What the editorial draws from them
Effects depend on genetic background, baseline vitamin D status, tissue context, and VDR partners. Low 25(OH)D may be a consequence of disease as well as a cause. Cardiovascular and cancer-prevention topics were not covered in depth.
MDPI's site blocked direct access, so the titles and summaries come from the papers' Crossref and PubMed records plus a copy of the editorial.
Sources:
- Rovito editorial, IJMS 2026;27:9463
- Briedė et al., VDR SNPs in atopic dermatitis
- Popov et al., VDR/partner composite elements
- Guo et al., vitamin D epigenetics and aging
- Fuentes-Barría et al., vitamin D and MASLD
- Valle et al., vitamin D in Down syndrome
Related in VitaminDWiki
- NAFLD and Vitamin D - many studies
- Liver problems, including hepatitis, are associated with low Vitamin D - Meta-analysis 2025
- Atopic Dermatitis risk is 55 percent higher if low vitamin D – Meta-analysis
- Understanding vitamin D deficiency - Editorial in Age and Aging
- Veterans and Vitamin D - many studies
- Nursing homes and Vitamin D - many studies
- Down syndrome people have even lower D levels if have additional Vitamin D diseases